683 Capital Management’s Acer Therapeutics Inc ACER Stock Holding History

683 Capital Management’s Portfolio ACER Stock Details ACER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-19,367	Closed	-$471K	–	187
2019 Q1	$471K	Hold	19,367	–	–	0.04%	108
2018 Q4	$390K	Hold	19,367	–	–	0.02%	128
2018 Q3	$597K	Buy	+19,367	New	+$519K	0.04%	106

Other funds holding ACER

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

683 Capital Management's ACER Position: Q2 2019 in Review

683 Capital Management sold out of Acer Therapeutics Inc (ACER) in Q2 2019, closing a stake of 19,367 shares — an estimated $471K sold.

683 Capital Management first reported a position in ACER in Q3 2018 and held it in 3 quarters. The position peaked at $597K in Q3 2018. 37 funds tracked by Wall St. Rank hold ACER as of Q2 2019.

683 Capital Management reported no remaining Acer Therapeutics Inc position as of Q2 2019 after selling out during the quarter.
683 Capital Management sold 19,367 Acer Therapeutics Inc shares in Q2 2019, an estimated $471K.
683 Capital Management first reported a position in Acer Therapeutics Inc in Q3 2018 and held it in 3 quarters.
683 Capital Management's Acer Therapeutics Inc position peaked at $597K in Q3 2018.
37 funds tracked by Wall St. Rank held Acer Therapeutics Inc as of Q2 2019.

Based on 683 Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.